Extended Data Fig. 5: Correlative analysis of GES levels and tumor shrinkage following treatment with spartalizumab in combination with dabrafenib and trametinib. | Nature Medicine

Extended Data Fig. 5: Correlative analysis of GES levels and tumor shrinkage following treatment with spartalizumab in combination with dabrafenib and trametinib.

From: Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

Extended Data Fig. 5

Association between a, T-cell–inflamed GES levels and b, PI3K pathway gene expression and best overall tumor reduction, based on Spearman correlation coefficient. n = 27 independent tumor biopsy specimens. CPM, counts per million; GES, gene expression signature.

Back to article page